Systematic review of feline diabetic remission: Separating fact from opinion

Gostelow, Ruth; Forcada, Yaiza; Graves, Thomas K.; Church, David; Niessen, Stijn

doi:10.1016/j.tvjl.2014.08.014

Cited by 41 publications

(57 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…If we had used this latter definition, there would have been 2 additional cats in remission in the exenatide ER group (but none in the placebo group) and thus, the rate of remission would have increased from 40% to 53.3% (8 of 15 cats). A recent literature review on feline diabetes suggested adopting the definition of diabetic remission used in the present study …”

Section: Discussionmentioning

confidence: 99%

Effect of the Glucagon‐like Peptide‐1 Analogue Exenatide Extended Release in Cats with Newly Diagnosed Diabetes Mellitus

Riederer

Zini

Salesov

et al. 2015

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundExenatide extended release (ER) is a glucagon‐like peptide‐1 analogue that increases insulin secretion, inhibits glucagon secretion and induces satiation in humans with type 2 diabetes mellitus. The use of exenatide ER is safe and stimulates insulin secretion in healthy cats.ObjectivesThe objective of this study is to assess the safety of exenatide ER and its effect on body weight, remission and metabolic control in newly diagnosed diabetic cats receiving insulin and a low‐carbohydrate diet.AnimalsThirty client‐owned cats.MethodsProspective placebo‐controlled clinical trial. Cats were treated with exenatide ER or 0.9% saline, administered SC, once weekly. Both groups received insulin glargine and a low‐carbohydrate diet. Exenatide ER was administered for 16 weeks, or in cats that achieved remission it was given for 4 weeks after discontinuing insulin treatment. Nonparametric tests were used for statistical analysis.ResultsCats in the exenatide ER and placebo groups had transient adverse signs including decreased appetite (60% vs. 20%, respectively, P = .06) and vomiting (53% vs. 40%, respectively, P = .715). Body weight increased significantly in the placebo group (P = .002), but not in cats receiving exenatide ER. Cats on exenatide ER achieved remission or good metabolic control in 40% or 89%, respectively, whereas in control cats percentages were 20% or 58% (P = .427 and P = .178, respectively).Conclusion and clinical importanceExenatide ER is safe in diabetic cats and does not result in weight gain. Our pilot study suggests that, should there be an additional clinically relevant beneficial effect of exenatide ER in insulin‐treated cats on rate of remission and good metabolic control, it would likely approximate 20% and 30%, respectively.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of the Glucagon‐like Peptide‐1 Analogue Exenatide Extended Release in Cats with Newly Diagnosed Diabetes Mellitus

Riederer

Zini

Salesov

et al. 2015

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…High rates of DM remission in treated hypersomatotropism also are indirect evidence of intrinsic β‐cells pathology in diabetic cats without hypersomatotropism. In such cats, with current treatment recommendations remission rates usually are much lower and remission is only temporary in approximately 30% of cases …”

Section: Dm Secondary To Endocrinopathies In Catsmentioning

confidence: 99%

“…Most cats treated with high dosages of glucocorticoids do not develop DM, supporting the theory of a pre‐existing subclinical DM state in those cats that do develop glucocorticoid‐induced DM. On the other hand, diabetic cats with a previous history of glucocorticoid administration are more likely to achieve diabetic remission . Additional research is needed to clarify the relationship between glucocorticoids and DM in the cat.…”

Section: Dm Secondary To Endocrinopathies In Catsmentioning

confidence: 99%

What's in a Name? Classification of Diabetes Mellitus in Veterinary Medicine and Why It Matters

Gilor

Niessen

Furrow

et al. 2016

Veterinary Internal Medicne

123

139

View full text Add to dashboard Cite

Diabetes Mellitus (DM) is a syndrome caused by various etiologies. The clinical manifestations of DM are not indicative of the cause of the disease, but might be indicative of the stage and severity of the disease process. Accurately diagnosing and classifying diabetic dogs and cats by the underlying disease process is essential for current and future studies on early detection, prevention, and treatment of underlying disease. Here, we review the current etiology‐based classification of DM and definitions of DM types in human medicine and discuss key points on the pathogenesis of each DM type and prediabetes. We then review current evidence for application of this etiology‐based classification scheme in dogs and cats. In dogs, we emphasize the lack of consistent evidence for autoimmune DM (Type 1) and the possible importance of other DM types such as DM associated with exocrine pancreatic disease. While most dogs are first examined because of DM in an insulin‐dependent state, early and accurate diagnosis of the underlying disease process could change the long‐term outcome and allow some degree of insulin independence. In cats, we review the appropriateness of using the umbrella term of Type 2 DM and differentiating it from DM secondary to other endocrine disease like hypersomatotropism. This differentiation could have crucial implications on treatment and prognosis. We also discuss the challenges in defining and diagnosing prediabetes in cats.

show abstract

“…Es wird daher davon ausgegangen, dass zumindest ein Teil der Katzen noch eine gewisse endogene Insulinproduktion besitzt oder wiedererlangen kann. In der Tat, ein gewisser Prozentsatz der diabetischen Katzen kann in Remission gehen und Insulin-unabhängig werden [2], obwohl dies nicht permanent auftreten muss. Im Gegensatz dazu tritt eine Remission bei diabetischen Hunden nur sehr selten auf, und das fast ausschließlich bei Hündinnen mit läufigkeitsinduziertem Diabetes nach der Kastration.…”

Section: Gibt Es Unterschiede Bei Der Insulinbehandlung Von Hund Und unclassified

Insulinbehandlung beim Hund – Was gilt es zu beachten?

Hazuchova¹

2019

kleintier konkret

View full text Add to dashboard Cite

Systematic review of feline diabetic remission: Separating fact from opinion

Cited by 41 publications

References 56 publications

Effect of the Glucagon‐like Peptide‐1 Analogue Exenatide Extended Release in Cats with Newly Diagnosed Diabetes Mellitus

Effect of the Glucagon‐like Peptide‐1 Analogue Exenatide Extended Release in Cats with Newly Diagnosed Diabetes Mellitus

What's in a Name? Classification of Diabetes Mellitus in Veterinary Medicine and Why It Matters

Insulinbehandlung beim Hund – Was gilt es zu beachten?

Contact Info

Product

Resources

About